Humacyte makes bioengineered human blood vessels, sold as Symvess, for hospitals and trauma centers. HUMA reports earnings on Wed, Nov 11, 2026.
Prices, price targets and earnings estimates for HUMA are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in HUMA in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HUMA is in one of them and how their past HUMA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Humacyte
Humacyte is a biotechnology company based in Durham, North Carolina, that makes bioengineered human tissues for surgical repair and replacement. Its main product is an acellular tissue engineered vessel sold under the name Symvess, which is approved in the United States as a vascular conduit for adults with arterial injury to the limbs. The company is developing additional vessels for uses such as dialysis access and peripheral artery disease. Its vessels are shipped to hospitals, trauma centers and outpatient surgical settings.
